In line with this, CD38+ CLL cells also show enhanced signaling induced by BCR or by anti-IgM/IgD antibody crosslinking, as well as a survival and proliferation advantage, compared to CD38− clones of the same individual (191). Here, BCR is linked to B-cell chronic lymphocytic leukemia.